Oncology
Study maps self-reinforcing SRSF1–AURKA–MYC circuit in pancreatic cancer cells
Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli
Researchers at Cold Spring Harbor Laboratory report they have identified a three-part molecular circuit involving SRSF1, Aurora kinase A (AURKA) and MYC that helps drive aggressive pancreatic ductal adenocarcinoma. In laboratory models, a splice-switching antisense oligonucleotide designed to alter AURKA splicing disrupted the circuit, reducing tumor-cell viability and triggering programmed cell death.
Two cancer patients have died at the University Hospital of Burgos after receiving a dose six times higher than prescribed of an oncology drug due to a human error in its preparation. Three other patients were affected, one in intensive care. The hospital manager attributes the incident to a failure in diluting the vial.
Imeripotiwa na AI Imethibitishwa ukweli
Researchers at the University of California San Diego report that certain cancer cells survive targeted therapies by using low-level activation of a cell-death–linked enzyme, enabling them to endure treatment and later regrow tumors. Because this resistance mechanism does not depend on new genetic mutations, it appears early in treatment and may offer a new target to help prevent tumor relapse.
Researchers at Spain's National Cancer Research Centre (CNIO) have developed a comprehensive catalog of mutational 'scars' in DNA caused by cancer. This breakthrough, published in Nature, could help bypass resistances to treatments like PARP inhibitors. The study analyzes thousands of tumor samples to identify key genetic patterns.
Imeripotiwa na AI Imethibitishwa ukweli
Vaccine therapy for malignant glioma is advancing, with calls for expedited approvals to treat this aggressive brain cancer. The approach has potential to save lives and is part of efforts for rare disease treatments. Early results indicate effectiveness without traditional chemo or radiation.